439239-92-6
- Product Name：Lasmiditan Hemisuccinate
- Molecular Formula：C42H42F6N6O8
- Purity：99%
- Molecular Weight：436.411
Product Details:
CasNo： 439239-92-6
Molecular Formula： C42H42F6N6O8
Buy High Quality Lasmiditan Hemisuccinate ,Reliable Quality 439239-92-6 Customized Supply
- Molecular Formula:0C4H6O4*C19H18F3N3O2
- Molecular Weight:436.411
- PSA：206.18000
- LogP:7.13100
Lasmiditan Hemisuccinate(Cas 439239-92-6) Usage
|
Description |
Lasmiditan Hemisuccinate is an oral medication primarily utilized for the acute treatment of migraine headaches in adults. Marketed under the brand name Reyvow, it is available as a white, crystalline powder with limited solubility in water, slight solubility in ethanol, and solubility in methanol. Lasmiditan acts as a highly selective serotonin 5-HT(1F) receptor agonist. |
| Function | Migraine headaches are characterized by severe throbbing pain often accompanied by symptoms like nausea, sensitivity to sound and light, and in some cases, aura. Lasmiditan works by binding to and activating 5-HT(1F) receptors, leading to the constriction of blood vessels and the inhibition of certain pain pathways associated with migraine attacks. |
| Uses | Approved by the U.S. Food and Drug Administration (FDA) in October 2019, Lasmiditan represents a significant advancement in migraine treatment due to its unique mechanism of action as a serotonin receptor agonist. It became available in February 2020 in the United States and received approval from the European Commission on August 17, 2022, further expanding its availability for migraine sufferers. Developed by Eli Lilly, Lasmiditan Hemisuccinate is considered a first-in-class medication for its novel approach in targeting migraine symptoms. |
439239-92-6 Relevant articles
2,2-DIMETHYL-N-[6-(1-METHYL-PIPERIDIN-4-CARBONYL)-PYRIDIN-2-YL]-PROPIONAMIDE, METHOD FOR PREPARING (6-AMINO-PYRIDIN-2-YL)-(1-METHYL-PIPERIDIN-4-YL)-METHANONE USING SAID COMPOUND, AND USE OF SAID COMPOUND IN THE PREPARATION OF LASMIDITAN
-
Page/Page column 22, (2021/01/23)
The present invention relates to a new i...
Lasmiditan Hemisuccinate: Selective Separation and Validation of Process Related Impurities by HPLC
P. Vijay Bhaskar, E. Venkata Reddy, M. Maheswar Reddy, A. Raghavendra
Paragraph 0094, (2021/08/06)
A rapid and efficient gradient RP-HPLC method was developed for the selective separation and determination of process related impurities of Lasmiditan Hemisuccinate (LDT) and its degradation products in bulk drugs. Chromatographic separation of five process related impurities of LDT was tested on Eclipse XDB C8, Primasil C18, Inertsil ODS 3V, and Zorbax SB-phenyl columns for efficient separation.
PROCESSES AND INTERMEDIATE FOR THE LARGE-SCALE PREPARATION OF 2,4,6-TRIFLUORO-N-[6-(1-METHYL-PIPERIDINE-4-CARBONYL)-PYRIDIN-2-YL]-BENZAMIDE HEMISUCCINATE, AND PREPARATION OF 2,4,6-TRIFLUORO-N-[6-(1-METHYL-PIPERIDINE-4-CARBONYL)-PYRIDIN-2-YL]-BENZAMIDE ACE
-
Page/Page column 37-40, (2021/01/29)
The embodiments of present invention pro...
439239-92-6 Upstream products
-
439239-90-4
Lasmiditan
-
110-15-6
succinic acid
-
5570-77-4
4-chloro-1-methylpiperidine
-
63463-36-5
(1-methyl-4-piperidyl)magnesium chloride
Relevant Products
-
PralsetinibCAS：2097132-94-8
-
IndapamideCAS：26807-65-8
-
BelumosudilCAS：911417-87-3
